Babson Diagnostics and Becton, Dickinson and Company (BD) have expanded their strategic collaboration to advance blood sample collection into new care settings.
It includes enabling patients to obtain blood samples at home for diagnostic testing.
The companies partnered in 2019 to develop a capillary blood collection and testing system to facilitate lab-quality, reduced-volume capillary blood collection in the retail settings by team members without any prior experience.
This system is currently in the advanced development stage.
According to the expanded deal, the companies will continue research and development to support self-collection, mobile services and at-home collection.
Furthermore, Babson and BD will broaden the types of blood tests that can be performed using small-volume blood collection beyond primary care-oriented tests.
The alliance also intends to develop diagnostic tests for paediatric usage.
The latest partnership intends to make the less-invasive blood sample collection method patient-centred and more convenient.
Under the long-term partnership, the companies are progressing the development of the blood testing ecosystem, which comprises the capillary collection technology of BD and Babson’s automated sample handling and analytical technologies.
These technologies are created to operate together to facilitate blood testing that needs only one-tenth of the sample volume of standard venipuncture methods while maintaining quality, precision, and the number and kind of tests that may be performed.
BD integrated diagnostics solutions president Brooke Story said: “This is a paradigm-shifting solution that addresses multiple unmet needs within the current health care system.
“Because it is less invasive and more convenient than the traditional venous blood draw method, capillary blood collection may lead to an improved patient experience, which in turn could help health care providers see better compliance among patients for routine blood testing.”
The latest development comes after BD reported revenues of $5bn in the first quarter (Q1) of 2022.